Scientists reported: “Our results clearly demonstrate that NIDA cannabis samples are substantially genetically different from most commercially available drug-type strains and share a genetic affinity with hemp samples in several of the analyses.”
Representatives Eleanor Holmes Norton, Barbara Lee, and Earl Blumenauer recently sent a letter to the Executive Director of the United States Botanic Garden, Dr. Saharah Moon Chapotin requesting that male and female hemp plants be on display.
The United States Department of Agriculture has issued interim rules governing the commercial cultivation of hemp. The rules are still subject to a mandatory 60-day public comment period following their publication in the Federal Register.
According to the report, “The number of acres of hemp licensed across 34 states totaled 511,442 in 2019 – more than quadruple the number of acres licensed from the previous year.”
A federal court has ordered the Drug Enforcement Administration to respond to a lawsuit charging the agency with failing to move forward with a 2016 policy to expand the total number of federally licensed marijuana cultivators.
Members of the US Senate Committee on Agriculture, Nutrition, and Forestry will hear expert testimony next week regarding the production of industrial hemp and hemp-derived products.
NORML has submitted written comments to the US Food and Drug Administration ahead of the agency’s scheduled hearing on the regulation CBD-infused products. The agency will be taking in person public testimony on Friday, May 31, with regard to the “manufacturing, product quality, marketing, labeling, and sale” of CBD-infused retail products.
Marijuana grown by the University of Mississippi for clinical research purposes is genetically divergent from strains of cannabis commercially available in retail markets, according to an analysis prepared by researchers at the University of Northern Colorado.